Kumatakenin
Based on 1 publication(s) in Google Scholar
Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor, with a Kd value of 2.94 μM for mouse ATG5. Kumatakenin increases the activities of caspase-3, caspase-8 and caspase-9, thereby inducing caspase-dependent apoptosis in ovarian cancer cells. Kumatakenin reduces the expression of chemokines and pro-oncogenic factors in ovarian cancer cells, and inhibits M2 macrophage polarization. Kumatakenin inactivates TRIM65 function, reduces the expression and stability of FASN, and thus inhibits the proliferation, migration, invasion and tumor progression of esophageal cancer cells. Kumatakenin interacts with ATG5 to reduce its protein level, decrease LC3 level, and reduce the number of autophagosomes in the hippocampus. Kumatakenin binds to Eno3 to upregulate its expression, reduce the stability and expression level of IRP1 mRNA, inhibit ferroptosis, alleviate intestinal inflammation, and restore epithelial barrier function. Kumatakenin enhances the efficacy of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production. Kumatakenin is applicable to research related to ovarian cancer, esophageal cancer, depression and colitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.31%
- CAS. Nr.: 3301-49-3
- Formel: C17H14O6
- Molecular Weight:314.29
-
Speicherung:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Kumatakenin
MoreAlle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16 | IC50 |
57.5 μM
Compound: 13
|
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25659770] |
| HeLa | IC50 |
8.1 μM
Compound: Kamatakenin
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784199] |
| MCF7 | IC50 |
10.3 μM
Compound: Kamatakenin
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31784199] |
| Neutrophil | IC50 |
0.7 μg/mL
Compound: 12
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
|
[PMID: 18163582] |
| Neutrophil | IC50 |
1.2 μg/mL
Compound: 12
|
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
|
[PMID: 18163582] |
In Vitro
Kumatakenin (0-100 μM; 48 h) induces dose-dependent inhibition of cell growth in human A2780 and SKOV3 ovarian cancer cells[1].
Kumatakenin (0-30 μM; 48 h) increases the proportion of sub-G1 phase cells, a marker of cell death, in human SKOV3 ovarian cancer cells without inducing cell cycle arrest. It triggers apoptotic cell death mediated by caspase-3 activation, and induces dose-dependent activation of caspase-3, caspase-8 and caspase-9[1].
Kumatakenin (0-30 μM; 24 h) dose-dependently downregulates the mRNA expression and secretion of MCP-1 and RANTES in human SKOV3 ovarian cancer cells[1].
Kumatakenin (0-40 μM; 24 h) dose-dependently reduces the mRNA and protein expression of M2 macrophage markers CD206 and Trem-2 in THP-1-derived tumor-associated macrophages (TAMs), decreases the mRNA expression of pro-tumor factors IL-10, VEGF, MMP-2 and MMP-9, reduces the protein expression levels of MMP-2 and MMP-9, and inhibits the secretion of IL-10 and VEGF[1].
Kumatakenin (0-40 μM; 12 h) dose-dependently reduces the mRNA expression levels of TRIM65 and FASN in KYSE410, TE-1, TE-10 and Case17 esophageal cancer cells[2].
Kumatakenin (0-40 μM; 12 h) inhibits the co-expression of TRIM65 and FASN in KYSE410, TE-1, TE-10 and Case17 esophageal cancer cells[2].
Kumatakenin (0-40 μM; 12 h) reduces the migration and invasion abilities of KYSE410, TE-1, TE-10 and Case17 esophageal cancer cells and downregulates the expression of pro-EMT markers in a dose-dependent manner, while upregulating the expression of anti-EMT markers after 12 h of treatment[2].
Kumatakenin (0-40 μM; 24 h) reduces palmitic acid (PA) (HY-N0830) and oleic acid (OA) (HY-N1446)-induced triglyceride accumulation in KYSE410 and TE-1 esophageal cancer cells in a dose-dependent manner after 24 h of co-treatment, and decreases intracellular lipid deposition and TRIM65 expression[2].
Kumatakenin (40 μM; 24 h) reduces the level of de novo palmitate synthesis from glucose in KYSE410 and TE-1 esophageal cancer cells[2].
Kumatakenin (40 μM) inhibits TRIM65-mediated K63-linked polyubiquitination of FASN in TRIM65-reconstituted KYSE410 and TE-1 esophageal cancer cells[2].
Kumatakenin (40-80 μM) reduces TRIM65-mediated K63-linked polyubiquitination of FASN in PA-treated, TRIM65-reconstituted KYSE410 and TE-1 esophageal cancer cells[2].
Kumatakenin (6.25-100 μM) binds to purified ATG5 protein with a Kd of 2.94×10-6 M[3].
Kumatakenin (1-20 μM) reverses the loss of HT-22 cell viability induced by Corticosterone (CORT) (HY-B1618) and regulates the expression levels of autophagy-related proteins in HT-22 cells (upregulating P62, downregulating ATG5 and LC3), but these effects are abrogated by ATG5 overexpression[3].
Kumatakenin (10-80 μM; 48 h) increases the viability of MODE-K mouse colonic epithelial cells treated with Erastin (HY-15763), reduces the level of lipid ROS in the cells, decreases intracellular iron levels and increases IRP1 protein levels, and accelerates the degradation rate of IRP1 mRNA in the cells in an Eno3-dependent manner[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human A2780 ovarian cancer cells, human SKOV3 ovarian cancer cells
-
Concentration:0, 1.563, 3.125, 6.25, 12.5, 25, 50, 100 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent cell growth inhibition in both A2780 and SKOV3 cells, with increasing inhibition observed at higher concentrations.
-
Cell Line:human SKOV3 ovarian cancer cells
-
Concentration:0, 5, 15, 30 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of cells in the sub-G1 phase from 2.33% (untreated) to 6.52% (5 μM), 8.58% (15 μM), and 21.06% (30 μM).
Did not induce significant cell cycle arrest in other phases.
-
Cell Line:human SKOV3 ovarian cancer cells
-
Concentration:30 μM
-
Incubation Time:0, 12, 24, 48 h
-
Result:Increased the total apoptotic cell population from 1.47% (0 h) to 11.14% (12 h), 23.01% (24 h), and 62.19% (48 h).
-
Cell Line:human SKOV3 ovarian cancer cells
-
Concentration:0, 5, 15, 30 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent increases in cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9, with fold changes (normalized to β-actin) ranging from 1 to >3 for all three caspases at increasing concentrations.
-
Cell Line:human SKOV3 ovarian cancer cells
-
Concentration:0, 5, 15, 30 μM
-
Incubation Time:24 h
-
Result:Reduced MCP-1 mRNA expression to ~90% (5 μM), ~75% (15 μM), and ~55% (30 μM) of control levels.
Reduced RANTES mRNA expression to ~90% (5 μM), ~65% (15 μM), and ~55% (30 μM) of control levels.
-
Cell Line:human SKOV3 ovarian cancer cells
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Reduced MCP-1 secretion to ~60% of control levels.
Reduced RANTES secretion to ~70% of control levels.
-
Cell Line:THP-1-derived tumour-associated macrophages (TAMs)
-
Concentration:0, 10, 20, 40 μM
-
Incubation Time:24 h
-
Result:Reduced CD206 mRNA expression to ~95% (10 μM), ~75% (20 μM), and ~65% of TAM control levels.
Reduced Trem-2 mRNA expression to ~95% (10 μM), ~85% (20 μM), and ~75% of TAM control levels.\nReduced IL-10 mRNA expression to ~95% (10 μM), ~35% (20 μM), and ~25% of TAM control levels.
Reduced VEGF mRNA expression to ~90% (10 μM), ~45% (20 μM), and ~35% of TAM control levels.
Reduced MMP-2 mRNA expression to ~95% (10 μM), ~30% (20 μM), and ~20% of TAM control levels.
Reduced MMP-9 mRNA expression to ~95% (10 μM), ~60% (20 μM), and ~50% of TAM control levels.
-
Cell Line:THP-1-derived tumour-associated macrophages (TAMs)
-
Concentration:30 μM
-
Incubation Time:24 h
-
Result:Reduced CD206 protein expression to ~40% of TAM control levels.
Reduced Trem-2 protein expression to ~60% of TAM control levels.\nReduced MMP-2 and MMP-9 protein expression compared to TAM control levels.
-
Cell Line:THP-1-derived tumour-associated macrophages (TAMs)
-
Concentration:40 μM
-
Incubation Time:24 h
-
Result:Reduced IL-10 secretion to ~65% of TAM control levels.
Reduced VEGF secretion to ~45% of TAM control levels.
-
Cell Line:KYSE410, TE-1, TE-10, Case17
-
Concentration:0 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:12 h
-
Result:Caused a dose-dependent reduction in TRIM65 mRNA expression in all four cell lines.
Caused a dose-dependent reduction in FASN mRNA expression in all four cell lines.
-
Cell Line:KYSE410, TE-1, TE-10, Case17
-
Concentration:40 μM
-
Incubation Time:12 h
-
Result:Inhibited the co-expression of TRIM65 and FASN in all four cell lines.
-
Cell Line:KYSE410, TE-10, TE-1, Case17
-
Concentration:0 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:12 h
-
Result:Caused a dose-dependent reduction in the migratory and invasive capabilities of KYSE410 and TE-10 cell lines.
Caused a dose-dependent decrease in mRNA expression of EMT-associated markers N-Cadherin, ZEB-1, Vimentin, and MMP13, and a dose-dependent increase in mRNA expression of E-cadherin and ZO-1 in KYSE410, TE-10, TE-1, and Case17 cells.
-
Cell Line:KYSE410, TE-1
-
Concentration:40 μM (concurrent with PA/OA treatment)
-
Incubation Time:24 h (concurrent with PA/OA treatment)
-
Result:Reduced lipid deposition and TRIM65 expression in both PA-treated and OA-treated KYSE410 and TE-1 cells.
-
Cell Line:MODE-K murine colonic epithelial cells
-
Concentration:10 μM, 80 μM
-
Incubation Time:48 h
-
Result:Reversed erastin-induced MODE-K cell death, increasing cell survival rates relative to erastin-only treatment.
In Vivo
Kumatakenin (0.56-2.25 mg/kg) alleviates CORT-induced depressive-like behaviors in male C57BL/6J mice by reducing plasma CORT levels, increasing plasma 5-HT, DA and BDNF levels, downregulating the expression of ATG5 and LC3 to inhibit excessive autophagy in the hippocampus, and restoring hippocampal neuronal structure and BDNF levels[3].
Kumatakenin (25-100 mg/kg; p.o.; once daily; for 9 consecutive days) significantly alleviates DSS (HY-116282C)-induced colitis in male C57BL/6 mice by upregulating Eno3 and modulating the Eno3-IRP1 axis to reduce cellular iron levels and inhibit ferroptosis in colonic epithelial cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c nude (male, 4 weeks old, 18-20 g, subcutaneously injected with 1×107 KYSE410 esophageal cancer cells/1×107 TE-1 esophageal cancer cells/1×107 TRIM65-overexpressing AdTRIM65 KYSE410 esophageal cancer cells)[2]
-
Dosage:80 mg/kg
-
Administration:p.o.; daily; 22 days
-
Result:Reduced tumor volume over the 22-day observation period (final mean tumor volume was lower than controls).
Reduced final tumor weight.
-
Animal Model:C57BL/6 (male, 28-35 g, DSS-induced colitis)[5]
-
Dosage:25 mg/kg; 100 mg/kg
-
Administration:i.g.; daily; 9 days
-
Result:Restored colonic mucosal bleeding, vascular patterns, intestinal villi atrophy, and reduced inflammatory cell infiltration.
Increased colon length, decreased Disease Activity Index score, alleviated diarrhea and rectal bleeding, and increased body weight and food intake.
Reduced colonic myeloperoxidase activity, and colonic levels of pro-inflammatory cytokines TNF-α and IL-6, and reduced serum fluorescein isothiocyanate-dextran levels, restoring epithelial barrier function.
Restored mitochondrial morphology in colonic epithelial cells, reduced colonic iron levels, decreased colonic malonaldehyde content, and reduced 4-hydroxynonenal expression in colonic tissues, suppressing ferroptosis.
Upregulated Eno3 protein expression in colonic tissues.
Reversed protective effects (improved colonoscopy findings, increased colon length, reduced Disease Activity Index, restored mitochondrial morphology, reduced colonic iron levels) when Eno3 was inhibited with ENOblock.
Reduced colonic IRP1 mRNA and protein expression, and promoted IRP1 mRNA degradation.
Blocked regulation of IRP1 expression when Eno3 was inhibited.
Chemical Information
-
CAS. Nr. 3301-49-3
-
Appearance Solid
-
Molecular Weight 314.29
-
Formel C17H14O6
-
Color Light yellow to green yellow
-
SMILES
O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC=C(O)C=C3)=C1OC
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 25 mg/mL (79.54 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Transepithelial/transendothelial electrical resistance assay
TEER measures electrical resistance across epithelial or endothelial monolayers cultured on permeable supports, and the readout reflects ionic conductance through the cell barrier, especially the paracellular pathway regulated by junctional integrity. TEER can be measured without destroying the monolayer and is commonly used before or during transport, permeability, barrier-disruption, and barrier-maturation experiments. TEER values are influenced by biological maturation and technical conditions; reported factors include temperature, medium formulation, passage number, electrode geometry, membrane properties, and junctional length during early monolayer maturation. Therefore, TEER should be interpreted with blank-insert subtraction, area normalization, repeated readings, and, when possible, orthogonal barrier readouts such as FITC-dextran flux or tight-junction staining.
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Reinheit & Dokumentation
-
Data Sheet (295 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Woo JH, et al. Effect of Kumatakenin Isolated From Cloves on the Apoptosis of Cancer Cells and the Alternative Activation of Tumor-Associated Macrophages. J Agric Food Chem. 2017 Sep 13;65(36):7893-7899. [Content Brief]
[3]. Li L, et al. Kumatakenin alleviates depressive-like behaviors by suppressing excessive autophagy in hippocampus via ATG5. Eur J Pharmacol. 2025;999:177688. [Content Brief]
[4]. Ripperger H, et al. Steroidal alkaloid glycosides from Solanum suaveolens. Phytochemistry. 1997;46(7):1279-1282. [Content Brief]
[5]. Arenbaoligao, et al. Kumatakenin inhibited iron-ferroptosis in epithelial cells from colitis mice by regulating the Eno3-IRP1-axis. Front Pharmacol. 2023;14:1127931. Published 2023 Mar 17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1818 mL | 15.9089 mL | 31.8177 mL | 79.5444 mL |
| 5 mM | 0.6364 mL | 3.1818 mL | 6.3635 mL | 15.9089 mL | |
| 10 mM | 0.3182 mL | 1.5909 mL | 3.1818 mL | 7.9544 mL | |
| 15 mM | 0.2121 mL | 1.0606 mL | 2.1212 mL | 5.3030 mL | |
| 20 mM | 0.1591 mL | 0.7954 mL | 1.5909 mL | 3.9772 mL | |
| 25 mM | 0.1273 mL | 0.6364 mL | 1.2727 mL | 3.1818 mL | |
| 30 mM | 0.1061 mL | 0.5303 mL | 1.0606 mL | 2.6515 mL | |
| 40 mM | 0.0795 mL | 0.3977 mL | 0.7954 mL | 1.9886 mL | |
| 50 mM | 0.0636 mL | 0.3182 mL | 0.6364 mL | 1.5909 mL | |
| 60 mM | 0.0530 mL | 0.2651 mL | 0.5303 mL | 1.3257 mL |
Keywords
- Kumatakenin
- 3301-49-3
- Apoptosis
- Autophagy
- Caspase
- Ferroptosis
- SARS-CoV
- apoptosis inducer
- autophagy inhibitor
- ovarian cancer
- esophageal cancer
- depression and colitis
- A2780cells
- SKOV3 cells
- TAMs
- KYSE410 cells
- TE-1 cells
- TE-10 cells
- Case17 esophageal cancer cells
- MODE-K mouse colonic epithelial cells
- Balb/c nude mice
- C57BL/6 mice
- Inhibitor
- inhibitor
- inhibit